Hematologic Cancer Fusion Analysis
GTR Test Accession: Help GTR000597220.2
CAP
CANCER
Last updated in GTR: 2023-01-04
Last annual review date for the lab: 2023-07-14 LinkOut
At a Glance
Therapeutic management
Hematologic neoplasm
ABL1 (9q34.12), ABL2 (1q25.2), AFDN (6q27), AICDA (12p13.31), ALK (2p23.2-23.1), ...
Molecular Genetics - RNA analysis: Next-Generation (NGS)/Massively parallel sequencing (MPS)
Patients who have been diagnosed to have hematologic malignancy
Not provided
Not provided
Ordering Information
Offered by: Help
Institute for Genomic Medicine (IGM) Clinical Laboratory
View lab's website
View lab's test page
Test short name: Help
Heme Archer
Manufacturer's name: Help
FusionPlex Pan-Heme Panel
Specimen Source: Help
Who can order: Help
  • Genetic Counselor
  • Health Care Provider
  • Licensed Physician
  • Nurse Practitioner
Test Order Code: Help
Lab contact: Help
Kathleen Schieffer, PhD, FACMG, Lab Director
614-722-5321
Contact Policy: Help
Laboratory can only accept contact from health care providers. Patients/families are encouraged to discuss genetic testing options with their health care provider.
How to Order: Help
Samples can be accepted 7 days a week (Monday - Sunday). All samples must be labeled with minimum of two patient identifying information (e.g. Patient Name and Date of Birth). Please Submit disease involved sample with a completed requisition form and a pathology report documenting the diagnosis. Please refer to …
View more
Order URL
Test development: Help
Manufactured (research use only; not FDA-reviewed)
Informed consent required: Help
No
Pre-test genetic counseling required: Help
No
Post-test genetic counseling required: Help
No
Recommended fields not provided:
Conditions Help
Total conditions: 1
Condition/Phenotype Identifier
Test Targets
Genes Help
Total genes: 147
Gene Associated Condition Germline or Somatic Allele (Lab-provided) Variant in NCBI
Methodology
Total methods: 1
Method Category Help
Test method Help
Instrument *
RNA analysis
Next-Generation (NGS)/Massively parallel sequencing (MPS)
* Instrument: Not provided
Clinical Information
Test purpose: Help
Therapeutic management
Target population: Help
Patients who have been diagnosed to have hematologic malignancy
Variant Interpretation:
What is the protocol for interpreting a variation as a VUS? Help
VUS and novel variants will be interpreted by trained variant analysis team member and a lab director using the current ACMG variant classification criteria.

Are family members with defined clinical status recruited to assess significance of VUS without charge? Help
No.

Will the lab re-contact the ordering physician if variant interpretation changes? Help
Yes. No systemic re-evaluation of previously reported variants/findings are currently performed. However, if the same variant/finding is identified in another patient and current assessment results in change in variant classification/interpretation, then the laboratory will recontact the ordering provider and issue an updated report.
Recommended fields not provided:
Technical Information
Test Comments: Help
CPT code updated 2023 to 81456
Availability: Help
Tests performed
Entire test performed in-house
Analytical Validity: Help
This assay detects gene fusions involving listed genes as a fusion gene partner. >99% of gene fusions involving these gene partners are detected by this assay if sample contains minimum blast/tumor % content requirement for this test (10% for fresh/frozen sample; 25% for FFPE sample).
Proficiency testing (PT):
Is proficiency testing performed for this test? Help
Yes

Method used for proficiency testing: Help
Formal PT program

PT Provider: Help
College of American Pathologists, CAP
VUS:
Laboratory's policy on reporting novel variations Help
Unusual or clinically significant novel variants will be communicated to the ordering provider via telephone call or email communication.
Recommended fields not provided:
Regulatory Approval
FDA Review: Help
Category: Not Applicable
Additional Information

IMPORTANT NOTE: NIH does not independently verify information submitted to GTR; it relies on submitters to provide information that is accurate and not misleading. NIH makes no endorsements of tests or laboratories listed in GTR. GTR is not a substitute for medical advice. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.